Acute tubulointerstitial nephritis in an HLA-B27-positive patient with axial spondyloarthritis being treated with adalimumab
Reumatol Clin (Engl Ed). 2019 May-Jun;15(3):179-181.
doi: 10.1016/j.reuma.2017.03.012.
Epub 2017 Jun 16.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Reumatología, Hospital General Universitario de Ciudad Real, Ciudad Real, España. Electronic address: d.castrocorredor@gmail.com.
- 2 Servicio de Nefrología, Hospital General Universitario de Ciudad Real, Ciudad Real, España.
- 3 Servicio de Anatomía Patológica, Hospital General Universitario de Ciudad Real, Ciudad Real, España.
Abstract
Antagonists of tumor necrosis factor-alpha (ATNF) are used for the treatment of multiple diseases such as psoriatic arthritis, Crohn's disease, ankylosing spondylitis and juvenile idiopathic arthritis, usually, when they are refractory to first-line treatment1. The use of ATNF has been associated with the induction of autoimmune diseases such as systemic lupus erythematosus-like disease, vasculitis, sarcoidosis-like diseases and, recently, acute granulomatous tubulointerstitial nephritis. We report a case of acute nongranulomatous tubulointerstitial nephritis in an HLA-B27-positive patient with axial spondyloarthritis and Crohn's disease being treated with adalimumab.
Keywords:
Acute tubulointerstitial nephritis; Adalimumab; Antagonistas del factor de necrosis tumoral-alfa; Crohn's disease; Enfermedad de Crohn; Espondiloartritis; Nefritis túbulo-intersticial aguda; Spondyloarthritis; Tumor necrosis factor-alpha antagonists.
Copyright © 2017 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.
MeSH terms
-
Adalimumab / adverse effects*
-
Adalimumab / therapeutic use
-
Antirheumatic Agents / adverse effects*
-
Antirheumatic Agents / therapeutic use
-
Biopsy
-
Crohn Disease / complications
-
Crohn Disease / drug therapy
-
Disease Susceptibility
-
HLA-B27 Antigen
-
Humans
-
Kidney / pathology
-
Male
-
Middle Aged
-
Molecular Targeted Therapy
-
Nephritis, Interstitial / chemically induced*
-
Nephritis, Interstitial / drug therapy
-
Nephritis, Interstitial / pathology
-
Spondylarthritis
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Antirheumatic Agents
-
HLA-B27 Antigen
-
Tumor Necrosis Factor-alpha
-
Adalimumab
Supplementary concepts
-
Acute Tubulointerstitial Nephritis